Advertisement

Cancer Therapeutics

Experimental and Clinical Agents

  • Beverly A. Teicher

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Cytotoxic Agents: Old and New

    1. Front Matter
      Pages 1-1
    2. Gerald J. Goldenberg, Malcolm J. Moore
      Pages 3-22
    3. Joel E. Wright
      Pages 23-79
    4. David B. Ludlum
      Pages 81-92
    5. Lloyd R. Kelland
      Pages 93-112
    6. Trevor W. Sweatman, Mervyn Israel
      Pages 113-136
    7. Beppino C. Giovanella
      Pages 137-152
    8. Yves Pommier
      Pages 153-174
    9. Marie-Christine Bissery, François Lavelle
      Pages 175-193
    10. Franco Zunino, Giovanni Capranico
      Pages 195-214
    11. Cynthia A. Romerdahl, Miguel F. Braña
      Pages 215-226
  3. Newer Strategies and Targets

    1. Front Matter
      Pages 227-227
    2. Nina Felice Schor
      Pages 229-240
    3. William G. Stetler-Stevenson
      Pages 241-261
    4. Jill A. Hendrzak, Michael J. Brunda
      Pages 263-282
    5. Stanley T. Crooke
      Pages 299-336
    6. Edward A. Sausville, Dan L. Longo
      Pages 337-370
    7. Walter A. Blättler, Ravi V. J. Chari, John M. Lambert
      Pages 371-394
    8. Judith S. Sebolt-Leopold
      Pages 395-415
    9. Peter I. Schrier, Susanne Osanto
      Pages 417-444
  4. Back Matter
    Pages 445-451

About this book

Introduction

Cancer drug discovery has been and continues to be a process of ingenuity, serendip­ ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti­ cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.

Keywords

DNA angiogenesis cancer cancer treatment cytokine cytokines drug drug development drug discovery gene therapy interferon research screening

Editors and affiliations

  • Beverly A. Teicher
    • 1
  1. 1.Dana-Farber Cancer InstituteBostonUSA

Bibliographic information